Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response

European Journal of Clinical Pharmacology

Volumn 66, Issue 5, 2010, Pages 525-530

  Molden, Espen ^a,b   Okkenhaug, Cecilie ^a   Solberg, Erik Ekker ^a  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Anticoagulation; Bleeding risk; CYP2C9 variant alleles; Cytochrome P450 enzymes; Genotyping; VKORC1 haplotype; Warfarin

Indexed keywords

CYTOCHROME P450 2C9; MENADIONE EPOXIDE; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX 1; VITAMIN K EPOXIDE REDUCTASE COMPLEX 2A; VITAMIN K EPOXIDE REDUCTASE COMPLEX 2B; WARFARIN; CYP2C9 PROTEIN, HUMAN; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE;

AGED; ANTICOAGULATION; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE DETECTION; HOMOZYGOSITY; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ALLELE; BLOOD CLOTTING; COMPARATIVE STUDY; DRUG EFFECT; GENETIC VARIABILITY; GENETICS;

AGED; ALLELES; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; FEMALE; GENETIC VARIATION; GENOTYPE; HAPLOTYPES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIXED FUNCTION OXYGENASES; WARFARIN;

EID: 77954505284     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0813-6     Document Type: Article

References (27)

1. http://www.legemiddelverket.no. Accessed 23 Nov 2009
2. http://www.reseptregisteret.no. Accessed 23 Nov 2009
3. Hermans JJ, Thijssen HH (1993) Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics. Br J Pharmacol 110:482-490
4. Kaminsky LS, Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74
5. Yamazaki H, Shimada T (1997) Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarinenantiomers. Biochem Pharmacol 54:1195-1203
6. http://www.cypalleles.ki.se. Accessed 23 Nov 2009
7. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H (1998) Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 63:519-528
8. Takahashi H, Wilkinson GR, Caraco Y, Muszkat M, Kim RB, Kashima T, Kimura S, Echizen H (2003) Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73:253-263
9. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, Lubetsky A, Roitelman J, Harats D, Halkin H, Ezra D (2001) Interindividual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 70:159-164
10. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, Padrini R (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702-710
11. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547
12. Stehle S, Kirchheiner J, Lazar A, Fuhr U (2008) Pharmacogenetics of oral anticoagulants: a basis for dose individualization. Clin Pharmacokinet 47:565-594
13. Limdi NA, Veenstra DL (2008) Warfarin pharmacogenetics. Pharmacotherapy 28:1084-1097
14. Sanderson S, Emery J, Higgins J (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 7:97-104
15. Schwarz UI, Ritchie MD, Bradford Y, Li C, Dudek SM, Frye-Anderson A, Kim RB, Roden DM, Stein CM (2008) Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med 358:999-1008
16. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, Muller CR, Wienker TF, Oldenburg J (2005) VKORC1 haplotypes and their impact on the inter-individual and interethnical variability of oral anticoagulation. Thromb Haemost 94:773-779
17. Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. J Med Genet 43:740-744
18. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293
19. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108967. htm. Accessed 23 Nov 2009
20. You JH, Tsui KK, Wong RS, Cheng G (2009) Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotypeguided dosing in patients starting warfarin therapy. Clin Pharmacol Ther 86:540-547
21. Rosove MH, Grody WW (2009) Should we be applying warfarinpharmacogenetics to clinical practice? No, not now. Ann Intern Med 151(270-3):W95
22. Bussey HI, Wittkowsky AK, Hylek EM, Walker MB (2008) Genetic testing for warfarin dosing? Not yet ready for prime time. Pharmacotherapy 28:141-143
23. Oake N, Jennings A, Forster AJ, Fergusson D, Doucette S, van Walraven C (2008) Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. Can Med Assoc J 179:235-244
24. Limdi NA, McGwin G, Goldstein JA, Beasley TM, Arnett DK, Adler BK, Baird MF, Acton RT (2008) Influence of CYP2C9 andVKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clin Pharmacol Ther 83:312-321
25. Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G (2007) Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians. Pharmacogenomics 8:1545-1550
26. Li C, Schwarz UI, Ritchie MD, Roden DM, Stein CM, Kurnik D (2009) Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. Blood 113:3925-3930
27. Hauta-Aho M, Tirkkonen T, Vahlberg T, Laine K (2009) The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 41:619-628